News & Updates

Show Multimedia Only

Novel adaptor enhances care for patients on NIV

12 Jul 2025 by

A new tube and inhaler adaptor (TIA) has been developed to improve the management of patients receiving noninvasive ventilation (NIV), and this device can be used across diverse clinical settings.

Novel adaptor enhances care for patients on NIV

12 Jul 2025

Depression tied to increased mortality in IPF

12 Jul 2025

Patients with idiopathic pulmonary fibrosis (IPF) and comorbid depression are less likely to initiate antifibrotic treatment and thus face an increased risk of death, as reported in a study.

Depression tied to increased mortality in IPF

12 Jul 2025

Nerandomilast safe, effective in autoimmune disease-related PPF

11 Jul 2025 by

Treatment with nerandomilast demonstrates efficacy in slowing forced vital capacity (FVC) decline in patients with autoimmune interstitial lung disease (ILD) similar to that seen in the overall trial population, reveals a subgroup analysis of the FIBRONEER-ILD study.

Nerandomilast safe, effective in autoimmune disease-related PPF

11 Jul 2025

Nerandomilast slows IPF progression in patients already on antifibrotic therapy

11 Jul 2025 by

The novel oral PDE4B* inhibitor nerandomilast slows the progression of idiopathic pulmonary fibrosis (IPF) in patients receiving antifibrotic treatment, as shown in the phase III FIBRONEER-IPF trial.

Nerandomilast slows IPF progression in patients already on antifibrotic therapy

11 Jul 2025

More cognitive issues, fewer heart problems after COVID-19 vs flu hospitalization in Asians

04 Jul 2025 by

Individuals hospitalized for COVID-19 vs seasonal influenza face a greater risk of cognitive impairment and fatigue but a lower risk of cardiac disorders as long-term consequences of infection, according to a retrospective population-based cohort study in Singapore.

More cognitive issues, fewer heart problems after COVID-19 vs flu hospitalization in Asians

04 Jul 2025

Wildfire smoke exposure ups risk of heart failure in older adults

03 Jul 2025

Exposure to wildfire smoke for an extended period may increase the risk of heart failure (HF) in older adults, particularly women and socially vulnerable populations, suggests a study.

Wildfire smoke exposure ups risk of heart failure in older adults

03 Jul 2025

Short-course antibiotic for paediatric CAP on par with long-course regimen

02 Jul 2025

A short-course antibiotic treatment for children with community-acquired pneumonia (CAP) demonstrates effectiveness similar to the long-course regimen but with fewer serious adverse events (AEs), reports a study.

Short-course antibiotic for paediatric CAP on par with long-course regimen

02 Jul 2025

Symptoms for ARIs in children vary across age groups

01 Jul 2025

Acute respiratory infections (ARIs) are associated with various symptoms across different age groups, according to a Korea study.

Symptoms for ARIs in children vary across age groups

01 Jul 2025

MMP7 predicts progression, death in antifibrotic-treated IPF

28 Jun 2025 by

Higher levels of matrix metalloprotease 7 (MMP7) pretreatment are predictive of 12-month progression and mortality among patients with idiopathic pulmonary fibrosis (IPF) who have been treated with antifibrotics, reveals a recent study.

MMP7 predicts progression, death in antifibrotic-treated IPF

28 Jun 2025

Original New Drug Application Approvals by US FDA (16-31 May 2025)

23 Jun 2025

New drug applications approved by US FDA as of 16-31 May 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 May 2025)

23 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

Novel adaptor enhances care for patients on NIV

Novel adaptor enhances care for patients on NIV

Depression tied to increased mortality in IPF

Depression tied to increased mortality in IPF

Nerandomilast safe, effective in autoimmune disease-related PPF

Nerandomilast safe, effective in autoimmune disease-related PPF

Nerandomilast slows IPF progression in patients already on antifibrotic therapy

Nerandomilast slows IPF progression in patients already on antifibrotic therapy

More cognitive issues, fewer heart problems after COVID-19 vs flu hospitalization in Asians

More cognitive issues, fewer heart problems after COVID-19 vs flu hospitalization in Asians

Wildfire smoke exposure ups risk of heart failure in older adults

Wildfire smoke exposure ups risk of heart failure in older adults

Short-course antibiotic for paediatric CAP on par with long-course regimen

Short-course antibiotic for paediatric CAP on par with long-course regimen

Symptoms for ARIs in children vary across age groups

Symptoms for ARIs in children vary across age groups

MMP7 predicts progression, death in antifibrotic-treated IPF

MMP7 predicts progression, death in antifibrotic-treated IPF

Original New Drug Application Approvals by US FDA (16-31 May 2025)

Original New Drug Application Approvals by US FDA (16-31 May 2025)